But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt. So, the natural question for Metsera (NASDAQ:MTSR) shareholders is whether they should be ...

For those venture-backed companies that have made their public-market debuts this year, the reception has been exceptionally ...

VESPER-1 and interim VESPER-3 data release expected in September 2025; Phase 3 initiation on track for late 2025 MET-233i (once-monthly amylin analog) delivered ...

Investing.com -- Metsera , Inc. (NASDAQ: MTSR ), a clinical-stage biopharmaceutical company focused on obesity and metabolic diseases, reported a wider-than-expected second quarter loss on Monday, ...

VESPER-1 and interim VESPER-3 data release expected in September 2025; Phase 3 initiation on track for late 2025 MET-233i (once-monthly amylin analog) delivered class-leading Phase 1 results including ...

Shares of ATAI Life Sciences NV ATAI -11.8% + Free Alerts fell sharply in pre-market trading after the company announced the ...

Cantor Fitzgerald reiterated an Overweight rating on Metsera Inc (NASDAQ: MTSR) following promising results from the company’s MET-233i obesity treatment. The research firm maintained its bullish ...

Metsera (NASDAQ:MTSR) stock jumps 16% as Wall Street continues to cheer positive Phase 1 data for its weight loss drug MET-233i. Read more here.

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for ...

Metsera's MET-233i shows sustained weight loss, long duration of action, and mild side effects in a Phase 1 trial, advancing its obesity treatment plans.

Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and ...

NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), today announced positive topline data from the Phase 1 clinical trial of MET-233i, an ultra-long acting amylin analog ...